Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Twist Bioscience Corp (NASDAQ: TWST) was $25.64 for the day, up 2.56% from the previous closing price of $25.0. In other words, the price has increased by $2.56 from its previous closing price. On the day, 1.97 million shares were traded. TWST stock price reached its highest trading level at $25.95 during the session, while it also had its lowest trading level at $24.8779.
Ratios:
Our analysis of TWST’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.90. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 04 ’25 when WERNER ROBERT F. sold 186 shares for $28.36 per share. The transaction valued at 5,276 led to the insider holds 49,780 shares of the business.
Leproust Emily M. sold 5,585 shares of TWST for $158,413 on Aug 04 ’25. The Chief Executive Officer now owns 639,721 shares after completing the transaction at $28.36 per share. On Aug 04 ’25, another insider, Green Paula, who serves as the SVP of Human Resources of the company, sold 1,255 shares for $28.36 each. As a result, the insider received 35,597 and left with 126,206 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 1547653376 and an Enterprise Value of 1390006144. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 3.23. Its current Enterprise Value per Revenue stands at 3.837 whereas that against EBITDA is -11.635.
Stock Price History:
The Beta on a monthly basis for TWST is 2.34, which has changed by -0.3996722 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $24.28. The 50-Day Moving Average of the stock is -24.93%, while the 200-Day Moving Average is calculated to be -36.60%.
Shares Statistics:
TWST traded an average of 1.20M shares per day over the past three months and 2022190 shares per day over the past ten days. A total of 60.17M shares are outstanding, with a floating share count of 57.31M. Insiders hold about 5.06% of the company’s shares, while institutions hold 114.35% stake in the company. Shares short for TWST as of 1752537600 were 10745056 with a Short Ratio of 8.94, compared to 1749772800 on 10308992. Therefore, it implies a Short% of Shares Outstanding of 10745056 and a Short% of Float of 20.26.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$2.32 and -$2.32 for the fiscal current year, implying an average EPS of -$2.32. EPS for the following year is -$2.45, with 1.0 analysts recommending between -$2.45 and -$2.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $98.5M to a low estimate of $96.73M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $84.71MFor the next quarter, 9 analysts are estimating revenue of $101.1M. There is a high estimate of $103.3M for the next quarter, whereas the lowest estimate is $99.04M.
A total of 9 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $375.52M, while the lowest revenue estimate was $374M, resulting in an average revenue estimate of $374.82M. In the same quarter a year ago, actual revenue was $312.97MBased on 10 analysts’ estimates, the company’s revenue will be $437.88M in the next fiscal year. The high estimate is $445.92M and the low estimate is $427M.
